Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Provided By GlobeNewswire
Last update: Nov 20, 2025
Phase 3 Study initiating in First Quarter of 2026
Single Pivotal Study Accelerates Potential FDA Approval
Timeline by Approximately 3 Years
